Abstract
Severe acute respiratory coronavirus 2 (SARS-CoV-2) infections have been associated with substantial presymptomatic transmission, which occurs when the generation interval—the time between infection of an individual with a pathogen and transmission of the pathogen to another individual—is shorter than the incubation period—the time between infection and symptom onset. We collected a dataset of 257 SARS-CoV-2 transmission pairs in Japan and jointly estimated the mean generation interval (3.7–5.1 days) and mean incubation period (4.4–5.7 days) as well as measured their dependence (Kendall’s tau of 0.4–0.6), taking into consideration demographic and epidemiological characteristics of the pairs. The positive correlation between the two parameters demonstrates that reliance on isolation of symptomatic COVID-19 cases as a focal point of control efforts is insufficient to address the challenges posed by SARS-CoV-2 transmission dynamics. Accounting for this dependence within SARS-CoV-2 epidemic models can also improve model estimates.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NML received a Japanese Ministry of Education, Culture, Sports, Science, and Technology (MEXT) graduate scholarship. HN received funding from a Health and Labor Sciences Research Grant (20CA2024 and 20HA2007), the Japan Agency for Medical Research and Development (AMED; JP20fk0108140 and JP20fk0108535s0101), the Japan Society for the Promotion of Science (JSPS) KAKENHI (21H03198), and the Japan Science and Technology Agency (JST) SICORP (e-ASIA) program (JPMJSC20U3).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Medical Ethics Board of the Graduate School of Medicine at Kyoto University (R2676). It uses data published online by public health jurisdictions in Japan.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data and code for this study are available on GitHub at https://github.com/nlinton/covid19_generationinterval
